CG Life, a specialized pharma agency built for the unique challenges of bringing therapies for rare and hard-to-treat diseases to market, has appointed Collette “Coco” Douaihy as the agency’s Chief Creative Officer (CCO) to lead the next evolution of CG Life’s creative offering for biopharma innovators. She joins the agency at a time when biopharma companies are facing growing pressure to connect scientific innovation with meaningful patient engagement in increasingly competitive therapeutic categories. To simultaneously elevate both creative and strategic capabilities at the agency, CG Life also promoted Senior Vice President of Strategy, Chris Weber, to the role of Chief Strategy Officer (CSO).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260519682641/en/
Collette “Coco” Douaihy, Chief Creative Officer, CG Life
Douaihy brings more than 26 years of experience leading award-winning creative for numerous pharmaceutical and medical marketing agencies. Most recently, she served as Global CCO, Health at Dentsu International. Before Dentsu, she was the Global CCO of Evoke and ECD at Digitas Health. In 2024, she was appointed as Pharma Jury President at Cannes Lions and was recognized by MM+M as one of the Healthcare Marketing Influencer 25, Class of 2024.
“Partnering with visionary companies to help bring transformative treatments to patients with rare and hard-to-treat diseases demands that a creative team be fueled by empathy,” said Douaihy. “Our team is deeply engaged in understanding not just the unmet clinical need, but the realities that those living with these diseases face every day. Rare disease demands rare creative — not louder but sharper, not safer but braver, not more but more meaningful. And we’re resolute in our commitment to making a difference.”
“Biopharma companies today are navigating an environment of increasingly complex launches, competitive landscapes, and stakeholder expectations. As clients rely on CG Life to deliver truly disruptive and innovative approaches for bringing new therapies to market, we must ensure that we are consistently offering them insightful and visionary creative direction and ideas,” said David Ormesher, CEO of CG Life. “With Coco at the head of our creative engines, CG Life will drive a creative vision for biopharma companies advancing and launching therapies in rare disease and high-unmet-need categories.”
CG Life’s promotion of Chris Weber to CSO underscores the agency’s belief that strong strategy is foundational to helping biopharma companies navigate critical growth and commercialization milestones. Bringing more than 30 years of healthcare agency experience to the role, he will continue to broaden CG Life’s strategic offering for clients across the biopharma and broader life sciences sector.
“For the past two years, Chris and his team have been instrumental in strengthening how CG Life partners with its biopharma and life science clients through deep strategic counsel and insight,” Ormesher continued. “He brings an intangible blend of experience, smarts, and leadership that is indispensable as we continue to elevate both our agency and the work we deliver for clients.”
About CG Life
Founded in 2003, CG Life is a specialized pharma agency built for the unique challenges of bringing therapies for rare and hard-to-treat diseases to market, where traditional commercialization models often fall short. CG Life partners with biopharma companies to navigate the complexity of rare disease commercial launches by combining deep scientific expertise, strategy-led activation of physician and patient communities, and results-driven engagement to support what’s best for patients. The result is faster, more effective launches in markets where insight, creativity, and credibility determine success.
Begin your journey at CGLife.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260519682641/en/
Media gallery
